News

We will be exhibiting at A4M’s LongevityFest 2024 conference December 13-15, 2024 in Las Vegas. We hope to see you there!

Visit us at booth # 1055 to see how we can help support your practice with medical products, IV supplies and pharmaceuticals. You’ll also learn about our featured product, ASCOR® - the only FDA-approved Ascorbic Acid Injection, (vitamin C).

Be sure to stop by and receive some special conference promotions!

December 13-15
Venetian and Palazzo Resort | Las Vegas
Booth # 1055

If you’d like to speak to us before the conference, feel free to contact us: answers@mcguff.com | (800) 854-7220.

To help support healthcare providers during the IV solution shortage, we’re offering free access to our Osmolarity Calculator until February 1, 2025, which will help easily calculate the right osmolarity when adjusting to new IV solutions. 

New Facility Allows for Greater Capacity of Pharmaceutical Manufacturing in the U.S.

In response to the recent nationwide shortage of IV solutions, triggered by unexpected damages at key manufacturing sites due to Hurricane Helene, we wanted to assure you of our unwavering commitment to your needs during this challenging period.

Great news - after three years of being on manufacturer back order, we now have 50% Dextrose Injection, USP available in stock.

On June 18th, the California Board of Pharmacy (CA BOP) held a regulation hearing on compounded drug preparations. McGuff’s management team, along with an estimated attendance of over 100 people, including medical professionals from diverse specialties, attended this three-hour subcommittee meeting. Their goal was to advocate for continued access to sterile compounded drugs from 503A compounding pharmacies.

We’ve been transitioning our 503A compounding pharmacy to a 503B outsourcing facility and are developing many compounded drugs for when we launch, as well as investigating others to develop in the future.

Good news - we now have three testosterone injection products available in stock!

The plastic syringe market has been negatively impacted by the FDA warnings about syringes manufactured in three specific factories in China. This widespread issue is causing supply chain shortages and delays due to increased demand for safe devices.

The good news is that McGuff has ample inventory of both BD and EXEL plastic syringes which are not included in the FDA’s safety alerts.

McGuff has three newly licensed company Designated Representatives, which brings our total to eight. 

California State Board of Pharmacy licensed Designated Representatives play a crucial role in the distribution of dangerous drugs or devices. Designated Representatives must have two years of hands-on experience and pass a rigorous state law examination to ensure the safe and compliant distribution of drugs and devices from McGuff Medical Products throughout California and the United States.

McGuff.com is our newly launched website that is a one-stop shop for medical professionals. We’ve developed this new site with our customers in mind, making it even more comprehensive, streamlined and user-friendly.

All three of our McGuff companies’ products are combined for this one cohesive site, making the shopping experience even better for our customers. If you’re looking for medical supplies, pharmaceuticals or compounded drugs, we’ve got you covered.

50 years ago, we started our business in a small garage in North Hollywood, California. Today we are five multinational businesses, and we owe our success to valued customers like yourself.  With your support we have continued to grow, and we would like to show our appreciation by providing you with a special discount.

McGuff Company, Inc. was named as “America’s IVC Defender” by the Riordan Clinic.  Ron Hunninghake, M.D. presented this award to Ronald M. McGuff, President of the McGuff Company, at the Riordan annual IVC Symposium in Wichita, Kansas.

I know the words ‘United States Congress’ and ‘Follow Through’ are generally never used in the same sentence, but in this case it actually just happened! Your letters sent to Congress via our website have paid off.